Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Clinical trial NCT06240143 · RECRUITING
Trial details
- NCT number
- NCT06240143
- Sponsor
- The Netherlands Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-08
- Primary completion
- 2029-07-01
- Enrollment
- 96
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.